Overview Phase 1 Study of Relative Bioavailability of PPI-668 New Tablet Versus Capsule Formulations Status: Completed Trial end date: 2014-12-01 Target enrollment: Participant gender: Summary This study will compare the blood levels of PPI-668 resulting from two different formulations - the current capsule and a new tablet, T003. Phase: Phase 1 Details Lead Sponsor: Presidio Pharmaceuticals, Inc.